Serum IL-17F does not predict poor response to im IFNβ-1a in relapsing-remitting MS

Neurology

Volumn 79, Issue 6, 2012, Pages 531-537

  Bushnell, S E ^a   Zhao, Z ^a   Stebbins, C C ^a   Cadavid, D ^a   Buko, A M ^a   Whalley, E T ^a   Davis, J A ^a   Versage, E M ^a   Richert, J R ^a   Axtell, R C ^b   Steinman, L ^b   Medori, R ^c  

^a BIOGEN   (United States)

^b STANFORD UNIVERSITY   (United States)

^c Biogen Idec International GmbH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERLEUKIN 17F;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELAPSE; TREATMENT RESPONSE;

EID: 84862741487     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318259e123     Document Type: Article

References (22)

1. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004;56:548 -555.
2. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996;6:259-274.
3. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717.
4. Killestein J, Polman CH. Determinants of interferon beta efficacy in patients with multiple sclerosis. Nat Rev Neurol 2011;7:221-228.
5. Trinchieri G. Type I interferon: friend or foe? J Exp Med 2010;207:2053-2063.
6. Axtell RC, de Jong BA, Boniface K, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010;16:406-412.
7. Oliver KG, Kettman JR, Fulton RJ. Multiplexed analysis of human cytokines by use of the FlowMetrix system. Clin Chem 1998;44:2057-2060.
8. Hilpert J, Beekman JM, Schwenke S, et al. Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers. J Neuroimmunol 2008;199:115-125.
9. Sellebjerg F, Datta P, Larsen J, et al. Gene expression analysis of interferon-beta treatment in multiple sclerosis. Mult Scler 2008;14:615-621.
10. Singh MK, Scott TF, LaFramboise WA, Hu FZ, Post JC, Ehrlich GD. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy. J Neurol Sci 2007;258:52-59.
11. Rani MR, Shrock J, Appachi S, Rudick RA, Williams BR, Ransohoff RM. Novel interferon-beta-induced gene expression in peripheral blood cells. J Leukoc Biol 2007;82: 1353-1360.
12. Gandhi KS, McKay FC, Schibeci SD, et al. BAFF is a Biological response marker to IFN-beta treatment in multiple sclerosis. J Interferon Cytokine Res 2008;28:529-539.
13. Wright JF, Guo Y, Quazi A, et al. Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J Biol Chem 2007;282:13447-13455.
14. Wright JF, Bennett F, Li BL, et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol 2008;181:2799-2805.
15. Chang SH, Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res 2007;17:435-440.
16. Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002;59:1507-1517.
17. Clanet M, Kappos L, Hartung H-P, Hohlfeld R, The European IFN beta-1a Dose-Comparison Study Investigators. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFN beta-1a Dose- Comparison Study. Mult Scler 2004;10:139 -144.
18. Gan G, Ma C, Wu J. Data Clustering: Theory, Algorithms, and Applications. ASA-SIAM Series on Statistics and Applied Probability 2007. Philadelphia: Siam; 2007.
19. Lee LF, Axtell R, Tu GH, et al. IL-7 promotes TH1 development and serum IL-7 predicts clinical response to interferon-beta in multiple sclerosis. Sci Transl Med 2011; 3:93ra68.
20. Ioannidis JP, Panagiotou OA. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA 2011;305:2200 -2210.
21. Kianifard F, Islam MZ. A guide to the design and analysis of small clinical studies. Pharmaceutical Statistics 2011;10: 363-368.
22. DeForge LE, Loyet KM, Delarosa D, et al. Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF, and IL-17AF. J Immunol Methods 2010;362:70-81.